NCT04448834撤回2 期
A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE® Antibody Blinatumomab (Blincyto) and Vincristine Sulfate Liposomal Injection (Marqibo) in Adult Subjects With Relapsed/Refractory Philadelphia Negative CD19+ Acute Lymphoblastic Leukemia
Dorothy Sipkins, MD, PhD3 个研究点 分布在 1 个国家开始时间: 2022年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 试验地点
- 3
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
Hypotheses: The Investigator hypothesizes that targeting ALL cells with 2 different modalities, ie liposomal vincristine sulfate as a microtubule inhibitor and blinatumomab as a BITE immuno-oncology therapy, will have at least additive benefits and allow an effective, safe therapeutic option for patients. Further, the Investigator hypothesizes that the combination will result in a high rate of response and thus allow enhanced immunologic recovery.
Primary Objectives To evaluate whether the combination will result in a median progression-free survival (PFS) of at least 1 year.
To evaluate if the complete remission/complete remission with incomplete hematological recovery (CR/CRi*) rate is ≧ 75% following 2 cycles in adult subjects with R/R Ph- ALL and duration of remission Secondary Objectives To evaluate the rate of Minimal Residual Disease (MRD) and duration To evaluate the proportion of patients who are able to progress to allogeneic transplantation To evaluate the safety of blinatumomab and liposomal vincristine sulfate in combination To evaluate the effect of the combination and response on measures of immune reconstitution
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with Ph-, CD19+ ALL, with any of the following:
- •Relapsed or refractory to at least 2 prior regimens ≥ 5% blasts in the bone marrow or peripheral blood or persistent extranodal/marrow site (such as skin).
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- •Age ≥ 18 years of age, at the time of informed consent.
- •Subject has provided informed consent. Those unable to provide consent for themselves will not be eligible.
- •Pts may have been exposed to either agent in the past if they had at least 6 months of response from start of therapy AND it has been at least 6 months since their last dose of either agent.
排除标准
- •History of malignancy other than ALL within 3 years prior to start of protocol-required therapy with the exception of:
- •Malignancy treated with curative intent and with no known active disease present for 2 years before enrollment and felt to be at low risk for recurrence by the treating physician
- •Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- •Adequately treated cervical carcinoma in situ without evidence of disease
- •Adequately treated breast ductal carcinoma in situ without evidence of disease
- •Prostatic cancer without evidence of progression for 1 year.
- •History or presence of clinically relevant CNS pathology as adult seizures, recent stroke (within 1 year), severe brain injuries, Parkinson's disease, psychosis
- •With the exception of CNS leukemia that is well controlled with therapy prior to enrolling on this study. A negative CNS evaluation for active disease is required within 3 months of enrollment in those with prior history within one year of active CNS disease .
- •Current severe autoimmune disease or history of autoimmune disease with potential CNS involvement such as lupus, sjogren's, psoriasis, multiple sclerosis, wegener's granulomatosis.
- •Allogeneic HSCT within 12 weeks prior to start of blinatumomab/marqibo
- •Any active acute Graft-versus-Host Disease (GvHD) grade 2 to grade 4 according to the Glucksberg criteria or active chronic GvHD requiring systemic treatment of more than 10 mg prednisone daily (or equivalent)
- •Cancer chemotherapy or immunotherapy within 2 weeks prior to start of blinatumomab/marqibo. Administration of dexamethasone and hydrea permitted within the 21 day screening period.
- •Subject received prior anti-CD19 therapy ARE eligible however if they received prior blinatumomab, however they are ineligible if they did not have a response to it lasting at least 6 months; also they are ineligible if they had exposure to blinatumomab within 6 months of starting therapy on this study.
- •Abnormal screening laboratory values as defined below:
- •AST (SGOT) and/or ALT (SGPT) and/or alkaline phosphatase ≥ 5 x upper limit of normal (ULN)
- •Total bilirubin ≥ 3 x ULN (unless related to Gilbert´s or Meulengracht disease)
- •Creatinine ≥ 3 ULN or creatinine clearance < 40 mL/min (calculated)
- •Known infection with human immunodeficiency virus (HIV) or chronic active infection with hepatitis B virus (PCR positive) or hepatitis C virus (PCR positive).
- •Subject is pregnant or breast feeding
- •Woman of childbearing potential and is not willing to use 2 highly effective methods of contraception while receiving blinatumomab/marqibo and for an additional 3 months after the last dose of protocol-specified therapy
- •Male who has a female partner of childbearing potential, and is not willing to use 2 highly effective forms of contraception for at least an additional 3 months after the last dose of protocol-specified therapy
- •Male who has a pregnant partner, and is not willing to use a condom during sexual activity for 3 months after the last dose of protocol-specified therapy
- •Currently receiving treatment in another investigational device or drug study or less than 30 days since ending treatment on another investigational device or drug study(s). The 30 days is calculated from day 1 of blinatumomab treatment.
- •Subject has known severe sensitivity to immunoglobulins or any of the products or components to be administered during dosing.
- •History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the Investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
研究组 & 干预措施
Treatment
Experimental
A single cycle of blinatumomab which includes 4 weeks of CIVI of blinatumomab followed by a 2 week treatment free interval
干预措施: Blinatumomab (Drug)
结局指标
主要结局
Progression-free survival (PFS)
时间窗: At 1 year
patient report
Complete remission/complete remission with incomplete hematological recovery (CR/CRi*) rate
时间窗: End of Cycle 2 (1 cycle is 6 weeks in duration)
lab reports
次要结局
- Minimal Residual Disease (MRD) and duration(End of Therapy (up to 58 weeks))
- Proportion of patients able to progress to allogeneic transplantation(End of study (up to 58 weeks))
- Safety of blinatumomab and liposomal vincristine sulfate in combination, as measured by rate of toxicity(Through all cycles of therapy (up to 58 weeks))
- Immune reconstitution, as measured by the immune reconstitution panel(End of study (up to 58 weeks))
研究者
Dorothy Sipkins, MD, PhD
Instructor in the Department of Medicine
Duke University
研究点 (3)
Loading locations...
相似试验
已完成
4 期
Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib MesylateProgressive Gastrointestinal Stromal TumorNCT00510354Novartis Pharmaceuticals28
已完成
2 期
Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous LeukemiaChronic Myelogenous LeukemiaNCT01294618Hospices Civils de Lyon60
招募中
2 期
Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)Primary Central Nervous System LymphomaNCT05549284Affiliated Hospital to Academy of Military Medical Sciences36
进行中（未招募）
1 期
Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab, gemcitabine, oxaliplatin and dexamethasone followed by Ibrutinib maitenance in patients with refractory/relapsed non-GCB diffuse large B-cell lymphoma non candidates to ASCTMedDRA version: 18.1Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851diffuse large B-cell lymphomaEUCTR2015-005390-21-ESGELTAMO64
进行中（未招募）
不适用
Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinical forms of Mantle Cell Lymphoma.Mantle Cell LyphomaMedDRA version: 18.1Level: HLTClassification code 10026798Term: Mantle cell lymphomasSystem Organ Class: 100000004851EUCTR2015-004158-17-ESGELTAMO (Grupo Cooperativo Español de Llinfoma/Trasplante Autólogo de Médula Ósea)